Today, we will see why Kadmon Holdings (KDMN) is an attractive pick in March 2020.
Company overview
Founded in 2009, Kadmon Holdings went public in 2016. The company is a late-stage biopharmaceutical company focused on the development and commercialization of small molecule therapies and biologics in areas of immune and fibrotic diseases as well as immune-oncology. The company is currently studying small molecule ROCK2 inhibitor, KD025, in cGVHD (chronic graft-versus-host disease) indication after at least 2 prior lines of systemic therapy, in an ongoing pivotal trial. The company is also studying its lead